Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TM5614 in congenital FGF23-related hypophosphatemic rickets/osteomalacia
jRCTs031210704Recruiting
- Sponsor
- Renascience
- Start
- Mar 2022
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of TM5614 in Congenital FGF23-related hypophosphatemic rickets (FGF23-HR) and FGF23-dependent hypophosphatemia, sponsored by Renascience. Primary endpoint: Change in serum phosphorus concentration. Started Mar 2022; status: recruiting.
02
Drugs
TM5614
03
Conditions
Congenital FGF23-related hypophosphatemic rickets (FGF23-HR)FGF23-dependent hypophosphatemia
Beyond the preview
Go deeper on jRCTs031210704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031210704.